-
Mashup Score: 0
Society of Urologic Oncology (SUO) 2021, intraluminal therapy for upper tract urothelial carcinoma (UTUC), OLYMPUS Trial, Endoluminal Light Activated Treatment of Upper Tract Urothelial Cancer (ENLIGHTED).
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
Society of Urologic Oncology (SUO), economic outcomes of hexaminolevulinate blue-light cystoscopy compared to white light cystoscopy for the diagnosis and monitoring of non-muscle invasive bladder cancer (NMIBC), Microsoft Excel with the @RISK simulation software.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Economic outcomes of hexaminolevulinate blue-light cystoscopy compared with white light cystoscopy for diagnosis and monitoring of #NMIBC: A 5-year, Medicare-based model. Presented by @ML_Creswell @GUMedicine. #SUO21 coverage by @zklaassen_md > https://t.co/vXUbaG9q2M @UroOnc https://t.co/K51fFXIbuZ
-
-
Mashup Score: 0
Society of Urologic Oncology (SUO) 2021, intraluminal therapy for upper tract urothelial carcinoma (UTUC), OLYMPUS Trial, Endoluminal Light Activated Treatment of Upper Tract Urothelial Cancer (ENLIGHTED).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Intraluminal therapy for upper tract urothelial carcinoma #UTUC. Presentation by @KSMurrayUro @MizzouUrology. #SUO21 written coverage by @rksayyid @mcg_urology on UroToday > https://t.co/FZcwnnxnIB @UroOnc https://t.co/MOyLuyP2NK
-
-
Mashup Score: 1
Society of Urologic Oncology (SUO), economic outcomes of hexaminolevulinate blue-light cystoscopy compared to white light cystoscopy for the diagnosis and monitoring of non-muscle invasive bladder cancer (NMIBC), Microsoft Excel with the @RISK simulation software.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Economic outcomes of hexaminolevulinate blue-light cystoscopy compared with white light cystoscopy for diagnosis and monitoring of #NMIBC: A 5-year, Medicare-based model. Presented by @ML_Creswell @GUMedicine. #SUO21 coverage by @zklaassen_md > https://t.co/vXUbaG9q2M @UroOnc https://t.co/OETAMfTLRE
-
-
Mashup Score: 0
Society of Urologic Oncology (SUO) 2021, intraluminal therapy for upper tract urothelial carcinoma (UTUC), OLYMPUS Trial, Endoluminal Light Activated Treatment of Upper Tract Urothelial Cancer (ENLIGHTED).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Intraluminal therapy for upper tract urothelial carcinoma #UTUC. Presentation by @KSMurrayUro @MizzouUrology. #SUO21 written coverage by @rksayyid @mcg_urology on UroToday > https://t.co/FZcwnnxnIB @UroOnc https://t.co/PfVN8Z2UPN
-
-
Mashup Score: 72021 Joseph A. Smith, Jr. Mentorship lecture: Discovery - PubMed - 2 year(s) ago
2021 Joseph A. Smith, Jr. Mentorship lecture: Discovery
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @m_e_nielsen: ICYMI—Dr Walsh’s #SUO21 🏆Mentorship Award presentation now published in @UrolOncol https://t.co/3h0FHU4FiW https://t.co/kF…
-
-
Mashup Score: 2Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies - 2 year(s) ago
I participated in “Understanding the Evolving Treatment Landscape in Bladder Cancer,” a CME/MOC activity from @PeerView
Source: api.learn2.peerview.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @SpeakJen: See a new #bladdercancer activity via @PeerView @PGrivasMDPhD @garysteinbergmd #SUO21 https://t.co/1zjGK9QjdG
-
-
Mashup Score: 1
Urine cytology specimen NGS was found to be a feasible and valid method of assessing genomic alterations in patients with upper tract urothelial carcinoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NGS via urine cytology specimens may represent a valid, minimally invasive profiling tool for assessing genomic alterations in UTUC #SUO21 @WesleyYipMD @UrologyMSK https://t.co/ktyDXFg6nD
-
-
Mashup Score: 1Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies - 2 year(s) ago
I participated in “Understanding the Evolving Treatment Landscape in Bladder Cancer,” a CME/MOC activity from @PeerView
Source: api.learn2.peerview.comCategories: Latest Headlines, Oncologists2Tweet-
RT @SpeakJen: See a new #bladdercancer activity via @PeerView @PGrivasMDPhD @garysteinbergmd #SUO21 https://t.co/1zjGK9QjdG
-
-
Mashup Score: 0
Society of Urologic Oncology (SUO), economic outcomes of hexaminolevulinate blue-light cystoscopy compared to white light cystoscopy for the diagnosis and monitoring of non-muscle invasive bladder cancer (NMIBC), Microsoft Excel with the @RISK simulation software.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Economic outcomes of hexaminolevulinate blue-light cystoscopy compared with white light cystoscopy for diagnosis and monitoring of #NMIBC: A 5-year, Medicare-based model. Presented by @ML_Creswell @GUMedicine. #SUO21 coverage by @zklaassen_md > https://t.co/vXUbaG9q2M @UroOnc https://t.co/lxhiEo7BTc
-
Intraluminal therapy for upper tract urothelial carcinoma #UTUC. Presentation by @KSMurrayUro @MizzouUrology. #SUO21 written coverage by @rksayyid @mcg_urology on UroToday > https://t.co/FZcwnnxnIB @UroOnc https://t.co/4n3bAkkOtz